Contact: info@alspinc.com
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
vvvNeurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 
44M people world wide
...are living with neurodegenerative disease and the impact is more than doubled when care givers and family members are included.

44M people world wide


-
...TBI increases risk of dementia by as much as two-fold
  
44M people world wide
44M People World Wide

...are living with neurodegenerative disease and the impact is more than doubled when care givers and family members are included...

Neurodegenerative Conditions increase with advancing age...
 
1 in 3 individuals over 80 risk Alzheimer's disease 
1 in 100 individuals over 85 risk Parkinson's disease 
1 in 10,000 risk Huntington's disease
 
...TBI increases risk of dementia
by as much as two-fold
 

 

        NEWS AND EVENTS

 

          April 6, 2016: ALSP, Inc. announced that the United States Patent and Trademark Office has issued a Notice of Allowance for claims directed to a

          group of ALP-496-related compounds, which ALSP had earlier licensed from Columbia University. Michael Pierschbacher, Ph.D, CEO, stated,

          "This issuance significantly increases the depth of our patent-approved pipeline of potential drug candidates." Read More... 


          March 1 - 2, 2016: ALSP Inc. presented its recent research findings at the 'GTC 2nd Protease Inhibitors in Drug Discovery' meeting in San Diego.

          As a Keynote speaker, Vivian Hook, Ph.D., UCSD, presented "Cathepsin B is a Validated Drug Target for Traumatic Brain Injury" and Gregory Hook,

          Ph.D., ALSP Inc., presented the poster "E64d, a Cysteine Protease Inhibitor, Provides a Viable Translational Opportunity for Development of

          Therapeutics for TBI". Read More...


          The following abstracts are available:


          Cathepsin B is a Validated Drug Target for Traumatic Brain Injury (TBI) and TBI-Related Brain Disorders
          E64d is a Translational Opportunity for Traumatic Brain Injury (TBI) Drug Development

                          

                                                                                              

          February 10, 2016: ALSP Inc. announced that it has appointed Col.(Retired) Dallas C. Hack, MD as Consultant for Medical Affairs

          in preparation for its move into clinical trials with its lead drug. Michael Pierschbacher, PhD, CEO, stated, "We are pleased to welcome Dallas Hack

          onto the ALSP team. We look forward to working with an individual of such practical knowledge and far-reaching experience in Traumatic Brain Injury

          (TBI). We look forward to drawing deeply on his broad experience and success as a clinician and researcher in this area as we enter into our next

          stage of growth, clinical development." Read More...


                                                                                                                  

          January 25 - 27, 2016: ALSP Inc. presented its recent research findings at the Keystone Symposia on Molecular and Cellular Biology in Santa Fe,

          New Mexico. Vivian Hook, Ph.D. UCSD, presented "Cathepsin B is a Validated Drug Target for Traumatic Brain Injury" during a session entitled

          "From Precision Medicine to Therapies (TBI)". Gregory Hook, Ph.D., ALSP, presented the poster "E64d, a Cysteine Protease Inhibitor, Provides a

          Viable Translational Opportunity for Development of Therapeutics for TBI", reviewing small molecule cysteine protease inhibitors shown to be

          effective in a number of TBI-related animal models and describing the selection of a lead clinical candidate. Read More...


          The following abstracts are available:


          Cathepsin B is a Validated Drug Target for Traumatic Brain Injury (TBI) and TBI-Related Brain Disorders

          E64d is a Translational Opportunity for Traumatic Brain Injury (TBI) Drug Development



September 15, 2015: ALSP Inc. is pleased to announce that it has entered into a Cooperative Research and Development Agreement (CRADA) with Walter Reed Army Institute of Research (WRAIR), Silver Spring, MD, to conduct traumatic brain injury (TBI) research on the Company's primary therapeutic target, cathepsin B, and the use of the Company's compounds to effect TBI outcomes in animal models. Read More... 

                                                                                                               


June 29, 2015: The poster entitled "Brain cathepsin B is elevated following trauma in both mild-closed and severe-penetrating traumatic brain injury models", was presented at the National Society of Neurotrauma, Santa Fe, NM, by researchers at the Walter Reed Army Institute of Research, Silver Spring, MD, and co-authored by Drs. Greg Hook, VP ALSP Research, and Vivian Hook, Professor, UCSD, and ALSP Scientific Advisor Chair Read More...

                                                                                                               


February 2, 2015: ALSP Inc. announced today that it has signed a license agreement with Columbia University to develop a series of proprietary compounds that are related to its lead clinical drug candidate, ALP-496, in the field of neurodegenerative disease. The compounds were identified by a team of investigators led by Dr. Ottavio Arancio, Associate Professor of Pathology and Cell Biology at Columbia University, and Dr. Gregory Thatcher, the Hans Valteich Chair of Medicinal Chemistry , College of Pharmacy, and Director of UICentre (drug discovery @ UIC) at the University of Illinois at Chicago Read More...



July 13, 2014: Drs. Greg Hook, VP Research, ALSP, and Vivian Hook, Professor, UCSD and ALSP Scientific Advisor Chair, presented at the American Alzheimer's International Conference (AAIC) in Copenhagen, Denmark July 12-17. The below abstracts are available:


Cysteine Protease Inhibitor, E64d, of Cathepsin B Reduces pGlu-Abeta and Abeta, and Improves Memory Deficits in the APPLon Mouse Model of AD

Cathepsin B Knockout Reduces pGlu-Ab and Ab, and Improves Memory Deficits, in the APPLon Mouse Model of AD



July 1, 2014: At national Neurotrauma Symposium, San Francisco, CA, Drs. Greg Hook, VP Research, ALSP and Vivian Hook, Professsor UCSD and ALSP Scientific Advisor Chair, made a poster presentation:


>The Cysteine protease cathepsin B is a key drug target and cysteine protease inhibitors are potential therapeutics for TBI. Please read Abstract



2012


2011


2010


2008 - 2009

representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.


>Deletion of the cathepsin B gene improves memory deficits in an Alzheimer's disease (AD) mouse model expressing APP with the wild-type beta-secretase site, representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

representing most AD patientsby Hook, V., Yu, J, Zhu, H., El-Amouri, S., Hook, G., and Kindy, M.

***